NCT07662018招募中不适用
Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 1
研究概览
简要总结
To collect information about treatment outcomes in pediatric and adolescent patients with relapsed/refractory germ cells tumors who receive GemDMC with an ASCT.
详细描述
Primary Objectives To estimate the overall survival (OS) rate and progression free survival (PFS) associated with pediatric and adolescent participants with relapsed/refractory germ cell tumors who receive tandem transplantation with gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) followed by carboplatin and etoposide (CE) as a second tandem transplantation.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female participants, greater than 1 month of age up to 21 years old. Neonates (birth to 1 month of age) will not be enrolled on this protocol.
- •Participants with relapsed/refractory seminomatous or nonseminomatous GCT who undergo an autologous stem cell transplantation (ASCT) with conditioning therapy including gemcitabine, docetaxel, melphalan, carboplatin (GemDMC) for germ cell tumors
- •As part of our analysis, we will also include participants aged 0-21 years old who have previously underwent ASCT with GemDMC
- •Participants who receive the following regimen:
- •High dose chemotherapy (HDC) course #1:
- •Gemcitabine/Docetaxel/Melphalan/Carboplatin D-6 Admission and start hydration D-5 Gemcitabine 1,500 mg/m2 IV Docetaxel 275 mg/m2 IV D-4 Gemcitabine 1,500 mg/m2 IV Melphalan 20 mg/m2 IV Carboplatin 250 mg/m2 IV D-3 Gemcitabine 1,500 mg/m2 IV Melphalan 20 mg/m2 IV Carboplatin 250 mg/m2 IV D-2 Gemcitabine 1,500 mg/m2 IV Melphalan 20 mg/m2 IV Carboplatin 250 mg/m2 IV D-1 Rest D0 Stem Cell infusion
- •Followed by HDC course #2 consisting of:
- •High-dose course #2: Carboplatin/Etoposide D-6 Admission and start hydration D-5 to -3 Etoposide 750 mg/m2 IV Carboplatin 700 mg/m2 IV D-2 Rest D-1 Rest D0 Stem Cell infusion
排除标准
- •Participants who do not or did not receive GemDMC as part of the conditioning regimen for an ASCT are not eligible for this study
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsNasopharyngeal CarcinomaNeuroblastomaRhabdomyosarcomaNCT07584499Sun Yat-sen University51
招募中
不适用
Clinical Outcomes of Arthroscopic Surgeries for Shoulder and Knee Sports InjuriesAthletic Injuries (C26.857.500.124)Anterior Cruciate Ligament Injuries Posterior Cruciate Ligament TearRotator Cuff InjuriesTibial Meniscus InjuriesShoulder Dislocation or SubluxationAnterior Cruciate Ligament InjuriesPosterior Cruciate Ligament TearNCT07501013Second Affiliated Hospital, School of Medicine, Zhejiang University500
招募中
1 期
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)NCT07465835Electra Therapeutics Inc.84
尚未招募
不适用
Comparison of Relapse Rate and Disease Severity among patients with Type 2 Lepra Reaction receiving Tofacitinib and Thalidomide separately as an adjuvant to systemic steroids: A Longitudinal Analytical StudyCTRI/2025/11/097093AIIMS Patna60
招募中
不适用
Predicting outcomes for children with status epilepticus using STEPS ScoreCTRI/2025/10/095805Not applicable126